Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.

Anti-TNFα trumps other treatments at preventing postoperative Crohn’s disease recurrence

10 Aug 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Anti-tumour necrosis factor α (anti-TNFα) agents are better than other conventional therapies at preventing the clinical, endoscopic and histological postoperative recurrence (POR) of Crohn’s disease (CD), reports a recent meta-analysis.

After applying the selection criteria, 14 studies emerged eligible for inclusion in the analysis, ten of which were randomized controlled trials (RCTs) by design. The resulting cumulative sample included 1,224 CD patient. Studies were retrieved from the databases of PubMed, Embase, CENTRAL and Web of Science.

The rate of clinical (odds ratio [OR], 0.508, 95 percent CI, 0.309–0.834; p=0.007), endoscopic (OR, 0.312; 0.199–0.489; p<0.001), severe endoscopic (OR, 0.195, 0.195–0.356; p<0.001) and histological (OR, 0.255, 0.106–0.611) POR was significantly lower in patients who were taking anti-TNFα as opposed to other nonbiological treatments.

In comparison, anti-TNFα therapy was significantly better than thiopurines only in terms of endoscopic POR (OR, 0.392, 0.241–0.639; p<0.001). Head-to-head comparison studies also showed that adalimumab and infliximab resulted in statistically comparable endoscopic POR rates (OR, 0.799, 0.329–1.940; p=0.620).

Eight of the included studies did not stratify patients according to risk groups. In this pooled sample of unselected CD patients, anti-TNFα treatment remained significantly better at preventing clinical (OR, 0.324, 0.158–0.664; p=0.002), endoscopic (OR, 0.225, 0.124–0.409; p<0.001) and severe endoscopic (OR, 0.248, 0.070–0.877) POR.

The relative efficacy of anti-TNFα therapies did not come at the cost of additional safety concerns, according to a pooled analysis of six studies. The rate of adverse (OR, 0.860, 0.457–1.617; p=0.639) and severe adverse (OR, 1.018, 0.641–1.617; p=0.94) events were comparable between patients who received anti-TNFα and other conventional treatments.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 6 days ago

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

6 days ago
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
6 days ago
Short sleep duration is associated with an increased risk of myocardial infarction (MI), according to prospective observational and Mendelian randomization (MR) analyses.
Tristan Manalac, 6 days ago
The addition of ezetimibe improves statin treatment in acute coronary syndrome (ACS) patients with dyslipidaemia and low eicosapentaenoic acid-to-arachidonic acid (EPA/AA) ratio, resulting in a lowered risk of cardiovascular events compared to monotherapy, according to a study presented at the recently concluded 2019 Congress of the European Society of Cardiology (ESC 2019) held in Paris, France.